Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Regenerative Therapy
- Vol. 10, 54-63
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Science and Technology Agency (15H04991, 15K15624, 18H04065, 24592560)
- Ministry of Health, Labour and Welfare
- Takeda Science Foundation
This publication has 33 references indexed in Scilit:
- Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressivaJournal of Clinical Investigation, 2017
- Statin treatment rescues FGFR3 skeletal dysplasia phenotypesNature, 2014
- iPS cell technologies: significance and applications to CNS regeneration and diseaseMolecular Brain, 2014
- Modeling Alzheimer’s Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular Aβ and Differential Drug ResponsivenessCell Stem Cell, 2013
- An Efficient Nonviral Method to Generate Integration-Free Human-Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood CellsStem Cells, 2013
- Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated PhenotypesCell Stem Cell, 2012
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- The Pendred syndrome gene encodes a chloride-iodide transport proteinNature Genetics, 1999
- Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS)Nature Genetics, 1997
- Association of congenital deafness with goitre (Pendred's syndrome): A study of 207 familiesAnnals of Human Genetics, 1964